Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment – Synergistic effect of thrombolysis and antioxidant –

Mei, Ting; Kim, Ah-Ram; Vong, Long Binh; Marushima, Aiki; Puentes, Sandra; Matsumaru, Yuji; Matsumura, Akira; Nagasaki, Yukio

doi:10.1016/j.biomaterials.2019.05.020

Cited by 91 publications

(73 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More importantly, ROS produced by cerebral ischemia-reperfusion can further damage brain tissues via neurodegeneration. To overcome this severe disease, various of nanomaterials including polymer NPs (Reddy and Labhasetwar, 2009;Petro et al, 2016;Ghosh et al, 2017;Mei et al, 2019;Mukherjee et al, 2019), ceria NPs (Zhang et al, 2018), polyoxometalate (POM) nanoclusters (Li et al, 2019a), and Framework Nucleic Acids (Li et al, 2019b) have been applied as protective agents, indicating the high efficiency in saving cerebral tissue via ROS scavenging. Notably, the high biocompatibility allows the polymer to be widely recruited for delivering antioxidant reagents [i.e., superoxide dismutase (Reddy and Labhasetwar, 2009), antioxidants catalas (Petro et al, 2016), and curcumin (Mukherjee et al, 2019), etc].…”

Section: Nanomedicine For Cerebral Irimentioning

confidence: 99%

“…Notably, the high biocompatibility allows the polymer to be widely recruited for delivering antioxidant reagents [i.e., superoxide dismutase (Reddy and Labhasetwar, 2009), antioxidants catalas (Petro et al, 2016), and curcumin (Mukherjee et al, 2019), etc]. Besides, a dual functional polymer NPs, t-PA@iRNP was successfully employed to induce thrombolytic and antioxidant therapies in cerebral tissue (Mei et al, 2019). With the encapsulation of tissue plasminogen activator (t-PA) and conjugation of 4amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), self-assemble t-PA@iRNP (∼50 nm) demonstrated an acidictriggered (pH = 6.2) thrombolytic activity and a significant decrease of ROS production in middle cerebral artery occlusion (MCAO) model mice.…”

Section: Nanomedicine For Cerebral Irimentioning

confidence: 99%

See 1 more Smart Citation

Reactive Oxygen Species (ROS)-Responsive Nanomedicine for Solving Ischemia-Reperfusion Injury

Chen

2020

Front. Chem.

View full text Add to dashboard Cite

Ischemia-reperfusion injury (IRI) is a severe condition for most organs, which could occur in various tissues including brain, heart, liver, and kidney, etc. As one of the major hazards, reactive oxygen species (ROS) is excessively generated after IRI, which causes severe damage inside tissues and further induces the following injury via inflammatory response. However, current medical strategies could not thoroughly diagnose and prevent this disease, eventually leading to severe sequelae by missing the best time point for therapy. In the past decade, various nanoparticles that could selectively respond to ROS have been developed and applied in IRI. These advanced nanomedicines have shown efficient performance in detecting and treating a series of IRI (e.g., acute kidney injury, acute liver injury, and ischemic stroke, etc.), which are well-summarized in the current review. In addition, the nano-platforms (e.g., anti-IL-6 antibody, rapamycin, and hydrogen sulfide delivering nanoparticles, etc.) for preventing IRI during organ transplantation have also been included. Moreover, the development and challenges of ROS-responsive nanomedicine are systematically discussed for guiding the future direction.

show abstract

Section: Nanomedicine For Cerebral Irimentioning

confidence: 99%

Section: Nanomedicine For Cerebral Irimentioning

confidence: 99%

Reactive Oxygen Species (ROS)-Responsive Nanomedicine for Solving Ischemia-Reperfusion Injury

Chen

2020

Front. Chem.

View full text Add to dashboard Cite

show abstract

“…In other studies, ROS-responsive as well as pH- and/or thrombin-responsive nanotherapies were examined for targeted treatment of thrombus formation [ 330 ], peripheral arterial disease [ 226 ], and ischemic stroke [ [331] , [332] , [333] , [334] ], offering promising therapeutic effects in different animal models. Collectively, studies by others and our group demonstrated that bioresponsive nanotherapies possess great potential for precision therapy of different inflammatory vascular diseases.…”

Section: Treatment Of Inflammatory Diseases By Bioresponsive Drug Delmentioning

confidence: 99%

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Ding

et al. 2020

Journal of Controlled Release

140

View full text Add to dashboard Cite

Inflammation is intimately related to the pathogenesis of numerous acute and chronic diseases like cardiovascular disease, inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases. Therefore anti-inflammatory therapy is a very promising strategy for the prevention and treatment of these inflammatory diseases. To overcome the shortcomings of existing anti-inflammatory agents and their traditional formulations, such as nonspecific tissue distribution and uncontrolled drug release, bioresponsive drug delivery systems have received much attention in recent years. In this review, we first provide a brief introduction of the pathogenesis of inflammation, with an emphasis on representative inflammatory cells and mediators in inflammatory microenvironments that serve as pathological fundamentals for rational design of bioresponsive carriers. Then we discuss different materials and delivery systems responsive to inflammation-associated biochemical signals, such as pH, reactive oxygen species, and specific enzymes. Also, applications of various bioresponsive drug delivery systems in the treatment of typical acute and chronic inflammatory diseases are described. Finally, crucial challenges in the future development and clinical translation of bioresponsive anti-inflammatory drug delivery systems are highlighted.

show abstract

“…Furthermore, the long half-life and high selectivity towards the lesions may have also contributed towards neuroprotection. Interestingly, Takahashi and his research colleagues also explored the use of RNPs to confer neuroprotection in a rat model of cerebral haemorrhage and a mouse model of transient cerebral ischaemia, which similarly yielded very optimistic results of neuroprotection [ 187 , 188 , 189 , 190 ]. To date, RNPs display very promising neuroprotective effects that call for further characterization and exploration.…”

Section: Nanoparticle-based Cns Theranosticsmentioning

confidence: 99%

Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders

Sim

Tarini

Dheen

et al. 2020

IJMS

View full text Add to dashboard Cite

Neurological disorders are the most devastating and challenging diseases associated with the central nervous system (CNS). The blood-brain barrier (BBB) maintains homeostasis of the brain and contributes towards the maintenance of a very delicate microenvironment, impairing the transport of many therapeutics into the CNS and making the management of common neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), cerebrovascular diseases (CVDs) and traumatic brain injury (TBI), exceptionally complicated. Nanoparticle (NP) technology offers a platform for the design of tissue-specific drug carrying systems owing to its versatile and modifiable nature. The prospect of being able to design NPs capable of successfully crossing the BBB, and maintaining a high drug bioavailability in neural parenchyma, has spurred much interest in the field of nanomedicine. NPs, which also come in an array of forms including polymeric NPs, solid lipid nanoparticles (SLNs), quantum dots and liposomes, have the flexibility of being conjugated with various macromolecules, such as surfactants to confer the physical or chemical property desired. These nanodelivery strategies represent potential novel and minimally invasive approaches to the treatment and diagnosis of these neurological disorders. Most of the strategies revolve around the ability of the NPs to cross the BBB via various influx mechanisms, such as adsorptive-mediated transcytosis (AMT) and receptor-mediated transcytosis (RMT), targeting specific biomarkers or lesions unique to that pathological condition, thereby ensuring high tissue-specific targeting and minimizing off-target side effects. In this article, insights into common neurological disorders and challenges of delivering CNS drugs due to the presence of BBB is provided, before an in-depth review of nanoparticle-based theranostic strategies.

show abstract

Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment – Synergistic effect of thrombolysis and antioxidant –

Cited by 91 publications

References 49 publications

Reactive Oxygen Species (ROS)-Responsive Nanomedicine for Solving Ischemia-Reperfusion Injury

Reactive Oxygen Species (ROS)-Responsive Nanomedicine for Solving Ischemia-Reperfusion Injury

Bioresponsive drug delivery systems for the treatment of inflammatory diseases

Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders

Contact Info

Product

Resources

About